The National Cancer Institute (NCI), part of the National Institutes of Health within the Department of Health and Human Services, has awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract to Azenta US Inc., doing business as Brooks Life Sciences Inc., for the provision of genomic characterization services to support the NCI's Center for Cancer Genomics research programs. The IDIQ contract has a $49,832,452 ceiling value and a period of performance from August 31, 2019 through August 30, 2024.
Under this IDIQ contract, Azenta has received multiple firm-fixed price delivery orders to provide services such as DNA whole exome sequencing and other genomic characterization to aid in cancer research studies. The contract does not utilize small business set-asides. The work is primarily performed at Azenta's facility in South Plainfield, New Jersey. The original solicitation sought proposals from qualified contractors capable of operating high-throughput, validated genomic characterization pipelines to support the NCI's goal of integrating genomic data into cancer research and clinical care.
Generated 8/9/24, 9:08 AM